Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Diversified Trust Co

Diversified Trust Co lifted its position in Biogen Inc. (NASDAQ:BIIB) by 0.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,926 shares of the biotechnology company’s stock after purchasing an additional 143 shares during the period. Diversified Trust Co’s holdings in Biogen were worth $3,506,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Nordea Investment Management AB raised its position in Biogen by 48.0% during the fourth quarter. Nordea Investment Management AB now owns 117,963 shares of the biotechnology company’s stock worth $17,901,000 after acquiring an additional 38,283 shares during the period. Everence Capital Management Inc. raised its position in shares of Biogen by 56.3% during the 4th quarter. Everence Capital Management Inc. now owns 4,360 shares of the biotechnology company’s stock worth $667,000 after purchasing an additional 1,570 shares during the last quarter. Centre Asset Management LLC lifted its stake in Biogen by 7.7% in the 4th quarter. Centre Asset Management LLC now owns 51,530 shares of the biotechnology company’s stock valued at $7,880,000 after buying an additional 3,698 shares in the last quarter. Versant Capital Management Inc boosted its holdings in Biogen by 228.7% in the 4th quarter. Versant Capital Management Inc now owns 401 shares of the biotechnology company’s stock worth $61,000 after buying an additional 279 shares during the last quarter. Finally, Principal Financial Group Inc. increased its stake in Biogen by 3.2% during the 3rd quarter. Principal Financial Group Inc. now owns 168,631 shares of the biotechnology company’s stock worth $32,687,000 after buying an additional 5,270 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Raymond James restated a “market perform” rating on shares of Biogen in a research report on Thursday, October 10th. Stifel Nicolaus cut shares of Biogen from a “buy” rating to a “hold” rating and set a $175.00 target price on the stock. in a research note on Monday, December 16th. Piper Sandler cut shares of Biogen from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $315.00 to $138.00 in a research report on Thursday, January 2nd. Robert W. Baird boosted their price target on shares of Biogen from $294.00 to $300.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. Finally, Wolfe Research started coverage on shares of Biogen in a report on Friday, November 15th. They issued a “peer perform” rating for the company. Sixteen investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $235.68.

Biogen Stock Down 0.1 %

NASDAQ:BIIB opened at $153.15 on Wednesday. Biogen Inc. has a 52 week low of $145.07 and a 52 week high of $258.71. The stock’s fifty day moving average is $158.96 and its two-hundred day moving average is $188.87. The stock has a market capitalization of $22.32 billion, a price-to-earnings ratio of 13.83, a price-to-earnings-growth ratio of 1.74 and a beta of -0.07. The company has a quick ratio of 0.80, a current ratio of 1.26 and a debt-to-equity ratio of 0.28.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $4.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.77 by $0.31. The firm had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.43 billion. Biogen had a return on equity of 14.98% and a net margin of 16.81%. Biogen’s revenue was down 2.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.36 EPS. Research analysts anticipate that Biogen Inc. will post 16.43 EPS for the current year.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.